Trial reportBJOG : an international journal of obstetrics and gynaecology2026
Placental Growth Factor Led Management of the Small for Gestational Age Fetus: Randomised Controlled Feasibility Study.
Trial report in BJOG : an international journal of obstetrics and gynaecology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo determine the feasibility of a trial investigating the optimal timing for the birth of women with a suspected late preterm and term SGA baby using either angiogenic biomarker-led care or standard care.
designA mixed methods study including a randomised feasibility trial, interviews, questionnaires and economic analysis.
settingTwo tertiary maternity hospitals in the UK. POPULATION: Women with suspected SGA pregnancies between 32
methodsWomen were randomised in a 3:1 ratio to biomarker-led care versus standard care. Biomarker tests were either revealed, with birth delayed until 40 weeks if normal (sFlt-1/PlGF < 38 pg/mL) and considered from 37 weeks if abnormal (sFlt-1/PlGF ≥ 38 pg/mL), or concealed alongside standard care.
main outcome measuresPrimary outcome was the feasibility of the study measured through the recruitment rate and adherence. Secondary outcomes were the qualitative, proof-of-concept and economic analyses.
resultsOut of 128 women invited to participate 78 women were recruited giving a recruitment rate of 60.1% (95% confidence interval 52%-69%). Sixty-seven of the 78 women consented to randomisation. Sixteen parents and 12 clinicians were interviewed. Fourty parents completed a questionnaire. Participants, partners and clinicians viewed the study as acceptable but experienced challenges in participation and delivering the study. There were no significant adverse events or differences in neonatal outcomes. Collection of health economics data was feasible.
conclusionsThe clinical, qualitative and economic results support the acceptability of utilising sFlt-1/PlGF to refine SGA management after 32
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.